Henry Meds semaglutide review
Advertised at $179, billed at $297. Position 12 of 14 on our board.
Updated 2026-09-18
DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.
Henry Meds prices semaglutide by format, and the spread between the cheapest and dearest is $118 a month.
Weekly injection about $297. Sublingual around $249, with a $179 tier. The $179 is the number in the advertising. No membership on any of them, which is a genuine mark in their favour.
The numbers
| Henry Meds · semaglutide | |
|---|---|
| Advertised | $179/mo |
| Membership | None |
| Billed | $297/mo |
| Advertised-to-billed gap | +$118/mo |
| Per year | $3,564 |
| Board position | 12 of 14, cheapest first |
The $179 tier is sublingual. The weekly injection is around $297/month.
Where the gap is
The gap is format, not fees. A reader comparing "$179 at Henry" against "$99 at Eden" is comparing a sublingual product with a weekly injection and a membership. Neither figure is wrong; the comparison is.
Against the board
Between roughly $2,148 and $3,564 a year depending on format. The prepaid oral route — three months for $537 paid in full — is where Henry competes properly.
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $99 | $149 | +$50 | +$63/mo |
| Ozari Health | $86 | $86 | none | — |
| Trimi | $99 | $99 | none | +$13/mo |
| Zealthy | $151 | $151 | none | +$65/mo |
| Mochi Health | $99 | $178 | +$79 | +$92/mo |
| Hims & Hers | $79 | $188 | +$109 | +$102/mo |
| PlexusDx | $129 | $189 | +$60 | +$103/mo |
| Eden | $99 | $198 | +$99 | +$112/mo |
How the programme works
Compounded GLP-1 provider with a strong oral and sublingual line alongside weekly injections, sold in monthly and prepaid multi-month blocks.
Verified facts
- Injectable tirzepatide listed at $399 for the first month and $449/month recurring.
- Oral tirzepatide tablets listed at $299 first month, $349/month recurring.
- Compounded semaglutide injection around $297/month; sublingual around $249/month with a $179/month tier.
- Three-month oral tirzepatide supply $1,047, or $891 paid in full.
- Three-month oral semaglutide supply $747, or $537 paid in full.
- Advertising states pricing "starts at $179/month", which corresponds to the lowest sublingual tier.
Checked 2026-09-18. This market re-prices without notice — anything older than a month is a starting point, not a quote.
For it
- No membership fee layered on top of medication.
- Real choice of sublingual, oral tablet and injection.
- Discounts for paying a multi-month block up front.
Against it
- Recurring injectable tirzepatide at $449/month is the most expensive compounded option here.
- The "$179" and "$297" figures describe different products, which readers routinely conflate.
- Month one and month two prices differ by $50.
Read this bit. The advertised "starts at $179" is the sublingual tier. Weekly injectable tirzepatide renews at $449/month.
Score
3 out of 5 on our rubric, which is fixed before assessment and published on how we rate.
| Criterion | Weight | Score |
|---|---|---|
| True monthly cost | 30% | 2.3 / 5 |
| Price honesty | 20% | 2.8 / 5 |
| Clinical support | 20% | 3.7 / 5 |
| Pharmacy sourcing | 15% | 3.6 / 5 |
| Cancelling | 15% | 2.9 / 5 |
Verdict
Buy the oral or sublingual product here. Buy the injection somewhere else.
More from the desk
- Coreage Rx semaglutide review
Advertised at $99, billed at $149. Position 1 of 14 on our board.
- Ozari Health semaglutide review
Advertised at $86 and billed at $86 — no gap. Position 2 of 14 on our board.
- Trimi semaglutide review
Advertised at $99 and billed at $99 — no gap. Position 3 of 14 on our board.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- Where the traps are
The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.